Sorafenib (brand name Nexavar) / TumMeta Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱

Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	RAF → MEK → ERK (MAPK)	↓ (primary)	↔ / ↓ (proliferating cells)	R/G	Reduced proliferative signaling	Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2	VEGFR / PDGFR (angiogenesis)	↓ tumor vascularization	↓ endothelial proliferation	R/G	Anti-angiogenic effect	Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3	Intrinsic apoptosis (Mcl-1↓, caspases↑)	↑	↔ / ↑ (dose-dependent)	R/G	Mitochondrial apoptosis	Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4	ROS	↑ (dose-dependent)	↔ / ↑ (high exposure)	P/R	Oxidative stress contribution	Redox stress may contribute to cytotoxicity and resistance mechanisms.
5	Ferroptosis	↑ (context-dependent)	↔	R/G	Lipid peroxidation vulnerability	Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6	PI3K/AKT/mTOR	↓ (secondary; model-dependent)	↔	R/G	Reduced survival signaling	Often compensatory pathway in resistance; combination target in trials.
7	HIF-1α	↓ (anti-angiogenic coupling)	↔	G	Reduced hypoxia signaling	Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8	NRF2	↑ (resistance-associated; context-dependent)	↔	R/G	Adaptive antioxidant response	NRF2 upregulation linked to sorafenib resistance in HCC.
9	Ca²⁺ signaling	↔ (stress-related)	↔	P/R	Not primary axis	Secondary to mitochondrial stress; not direct target.
10	Clinical Translation Constraint	↓ (constraint)	↓ (toxicity)	—	Resistance + tolerability limits	Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)

TumMeta, Cancer Metastasis: Click to Expand ⟱

Source:

Type:

Cancer metastasis is the process by which cancer cells spread from the original (primary) tumor to other parts of the body, forming new (secondary) tumors. This occurs when cancer cells invade surrounding tissues, enter the bloodstream or lymphatic system, and travel to distant organs or tissues.

Scientific Papers found: Click to Expand⟱

1168-

IVM,

SRF,

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

in-vitro,

HCC,

TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State ⓘ

CSCsMark↓, 1, EMT↓, 1, mTOR↓, 1, STAT3↓, 1,

Migration ⓘ

TumMeta↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TumMeta, Cancer Metastasis

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells